AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.
Hosted on MSN20d
Is AbbVie Stock a Buy?
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on AbbVie (ABBV – Research Report) on January 31. The company’s shares opened ...
In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock ...
TD Cowen upped their price target on AbbVie from $195.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Bank of America reiterated a ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics.